Ivermectine Sigillata

Ivermectin, the active ingredient in Ivermectine Sigillata, is an anthelmintic presented as a tablet oral dosage form for oral use. It is employed to treat a range of parasitic infections in humans, including river blindness, strongyloidiasis, scabies and lice infestations.

GNH USA supplies Ivermectine Sigillata as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing full regulatory documentation for export.

Ivermectin is an oral antiparasitic that targets a variety of helminth and ectoparasite infections. - Onchocerciasis (river blindness): reduces microfilarial load and helps prevent disease progression. - Strongyloidiasis: eliminates intestinal larvae and prevents disseminated infection. - Scabies: eradicates Sarcoptes scabiei mites, relieving itching and skin lesions. - Pediculosis (lice infestation): kills head and body lice, interrupting the life cycle. - Other intestinal helminth infections: treats infections such as ascariasis and hookworm by killing adult worms.

Ivermectin may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Dizziness: transient light‑headedness. - Nausea: mild stomach upset. - Diarrhea: loose stools after dosing. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Neurological events: seizures or encephalopathy. - Hepatotoxicity: significant elevation of liver enzymes. - Visual disturbances: optic neuritis or blurred vision.

When prescribing ivermectin, clinicians should consider several safety measures to minimize risk. - Assess for co‑existing CNS disorders: avoid in patients with known seizures. - Review concomitant medications: evaluate for interactions that affect CYP3A4. - Pregnancy and lactation: use only if potential benefit outweighs risk